(4-oxooct-7-enyl)carbamic acid tert-butyl ester | 887402-83-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-oxooct-7-enyl)carbamic acid tert-butyl ester
• 英文别名: tert-butyl 4-oxooct-7-enylcarbamate；tert-butyl N-(4-oxooct-7-enyl)carbamate
• CAS: 887402-83-7
• 化学式: C₁₃H₂₃NO₃
• 分子量: 241.331
• InChiKey: DGSMHGDOIYDEQS-UHFFFAOYSA-N

物化性质

• 沸点：
  362.3±25.0 °C(Predicted)
• 密度：
  0.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-oxooct-7-enyl)carbamic acid tert-butyl ester 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 1,2-双(二苯基膦)乙烷 作用下， 以 二氯甲烷 、 2,2,2-三氟乙醇 为溶剂， 反应 88.5h， 生成 tert-butyl (4-acetamido-4-(tert-butylcarbamoyl)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)octyl)carbamate
  参考文献：
  名称：

  [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  [FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。

  公开号：

  WO2011133653A1
• 作为产物：
  描述：

  N-BOC-GAMMA-氨基丁酸 在 碘 、 magnesium 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 (4-oxooct-7-enyl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  [FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES

  摘要：

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。

  公开号：

  WO2011133653A1

文献信息

• PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT
  申请人：Wiessler Manfred

  公开号：US20100016545A1

  公开（公告）日：2010-01-21

  The present invention relates to a process for linking two molecules by means of a Diels Alder reaction with inverse electron requirement (DARinv), comprising the following steps: reaction of a (a) triazine or tetrazine with one or more electron-attracting substituents on the ring as a diene component, the electron-attracting substituents being selected from: COOR C(O)NR 2 CX 3 (X=halogen) halogen CN SO 2 —R or SO 3 —R PR 2 wherein R═H, alkyl, aryl, heterocycle, which in turn may be substituted, where appropriate, with alkyl, OH, SH, halogen, aryl, heterocycle, nitro, carboxyamido or amine group. —heterocyclic rings having 1, 2 or 3 N, O or S atoms with a ring size of 5 or 6 ring members, which are substituted with at least one carboxyl, sulfonic acid or phosphone group with (b) an isolated double bond or triple bond in a (hetero)carbocyclic ring or an isolated olefinic double bond or triple bond in a linear or branched hydrocarbon chain which may also contain heteroatoms, where appropriate, as a dienophile component.

  本发明涉及一种利用逆电子需求的Diels-Alder反应（DARinv）将两种分子通过连接的方法，包括以下步骤：将（a）三嗪或四嗪与环上的一个或多个吸电子取代基反应作为二烯组分，所述吸电子取代基被选择自：COOR、C（O）NR2、CX3（X=卤）、卤、CNSO2—R或SO3—RPR2，其中R=H、烷基、芳基、杂环，后者可能被适当地取代，如有必要，可用烷基、OH、SH、卤、芳基、杂环、硝基、羧基氨基或胺基团取代；（b）一种孤立的双键或三键存在于（杂）碳环上，或者一种孤立的烯烃双键或三键存在于线性或支链烃链中，该链也可能含有杂原子，如有必要，作为二烯酰组分。
• Toward the Total Synthesis of FR901483:  Concise Synthesis of the Azatricyclic Skeleton
  作者：Suvi T. M. Simila、Stephen F. Martin

  DOI：10.1021/jo070732a

  日期：2007.7.1

  that could be transformed into (−)-FR901483 first required the development of a new protecting group, the 1-ethylallyloxycarbamate group, for amines that may be removed under mild conditions. However, because the stereoselectivity in a key step in which a functionalized allyl zinc reagent was added to an intermediate hydroxy-substituted imine was low, this route to (−)-FR901483 is no longer being pursued

  FR901483的氮杂三环核的简明合成已使用一种新颖的策略完成，该策略涉及将亲核性加成至N-酰基亚胺离子，闭环易位，非对映选择性硼氢化和内酯-内酰胺重排，在初步模型研究。将该方法扩展到可以转化为（-）-FR901483的功能更高的中间体的合成中，首先需要开发新的保护基团1-乙基烯丙氧基氨基甲酸酯基团，以便在温和条件下可以除去胺。但是，由于在将官能化的烯丙基锌试剂添加至中间体羟基取代的亚胺中的关键步骤中的立体选择性低，因此不再寻求这种通往（-）-FR901483的途径。
• INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Van Zandt Michael

  公开号：US20120083469A1

  公开（公告）日：2012-04-05

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据公式I和公式II的化合物是Arginase I和II活性的有效抑制剂：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，D，M，X和Y的定义如规范中所述。该发明还提供了这些化合物的制药组合物和使用它们治疗或预防与Arginase活性相关的疾病或病况的方法。
• Inhibitors of arginase and their therapeutic applications
  申请人：Van Zandt Michael

  公开号：US09040703B2

  公开（公告）日：2015-05-26

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据公式I和公式II，化合物是Arginase I和II活性的有效抑制剂：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，D，M，X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们的用于治疗或预防与Arginase活性相关的疾病或病况的方法。
• Synthetic studies toward the immunosuppressant FR901483. Facile construction of the azatricyclic skeleton
  作者：Suvi T.M. Simila、Andreas Reichelt、Stephen F. Martin

  DOI：10.1016/j.tetlet.2006.02.116

  日期：2006.4

  A concise synthesis of the azatricyclic core structure of FR901483, a potent immunosuppressant, has been accomplished. The key elements of the approach involve a nucleophilic addition to an acyl iminium ion, a ring closing metathesis and a lactone-lactam rearrangement to provide the tricyclic structure. (c) 2006 Elsevier Ltd. All rights reserved.